CN104703595B - 涉及血管破坏剂和靶向缺氧的药剂的组合疗法 - Google Patents

涉及血管破坏剂和靶向缺氧的药剂的组合疗法 Download PDF

Info

Publication number
CN104703595B
CN104703595B CN201380035499.3A CN201380035499A CN104703595B CN 104703595 B CN104703595 B CN 104703595B CN 201380035499 A CN201380035499 A CN 201380035499A CN 104703595 B CN104703595 B CN 104703595B
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
aryl
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380035499.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104703595A (zh
Inventor
丹尼尔·J·英格利斯
蒂娜·C·拉夫拉诺斯
加布里埃尔·克雷米迪奥蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902291A external-priority patent/AU2012902291A0/en
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Publication of CN104703595A publication Critical patent/CN104703595A/zh
Application granted granted Critical
Publication of CN104703595B publication Critical patent/CN104703595B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380035499.3A 2012-06-01 2013-06-03 涉及血管破坏剂和靶向缺氧的药剂的组合疗法 Expired - Fee Related CN104703595B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902291A AU2012902291A0 (en) 2012-06-01 Combination Therapy
AU2012902291 2012-06-01
PCT/AU2013/000581 WO2013177633A1 (en) 2012-06-01 2013-06-03 Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia

Publications (2)

Publication Number Publication Date
CN104703595A CN104703595A (zh) 2015-06-10
CN104703595B true CN104703595B (zh) 2017-07-28

Family

ID=49672192

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380035499.3A Expired - Fee Related CN104703595B (zh) 2012-06-01 2013-06-03 涉及血管破坏剂和靶向缺氧的药剂的组合疗法

Country Status (9)

Country Link
US (1) US20150133401A1 (enExample)
EP (1) EP2854796B1 (enExample)
JP (1) JP6005855B2 (enExample)
CN (1) CN104703595B (enExample)
AU (2) AU2013204313C1 (enExample)
CA (1) CA2874778A1 (enExample)
IL (1) IL235927A (enExample)
NZ (1) NZ630465A (enExample)
WO (1) WO2013177633A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978640C (en) 2015-03-05 2023-05-23 Bionomics Limited Combination treatment protocol
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
CN107530340B (zh) * 2015-03-06 2021-06-08 大连万春布林医药有限公司 治疗脑肿瘤的方法
WO2017011399A1 (en) 2015-07-13 2017-01-19 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
MX2019009020A (es) 2017-02-01 2019-11-12 Beyondspring Pharmaceuticals Inc Metodo para reducir la neutropenia.
EP4176876A1 (en) * 2017-09-14 2023-05-10 Lankenau Institute for Medical Research Methods and compositions for the treatment of cancer
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
CN110680824A (zh) * 2018-07-05 2020-01-14 深圳艾欣达伟医药科技有限公司 埃夫索胺的抗癌医药用途
CN109675039A (zh) * 2018-12-21 2019-04-26 中国科学院长春应用化学研究所 药物组合、抗肿瘤的药物和应用
CN112755188B (zh) * 2019-11-01 2022-03-08 中国科学院微生物研究所 Shmt2抑制剂在制备抑制膀胱癌细胞生长和转移的药物中的应用
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
JP7762796B2 (ja) 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
JP2024531479A (ja) 2021-08-27 2024-08-29 アセンタウィッツ ファーマシューティカルズ リミテッド 凍結乾燥製剤溶液および凍結乾燥製剤、ならびにそれらの方法および使用
WO2023174319A1 (zh) 2022-03-15 2023-09-21 深圳艾欣达伟医药科技有限公司 治疗brca突变癌症患者的方法
EP4509127A1 (en) 2022-04-15 2025-02-19 Ascentawits Pharmaceuticals, Ltd. Method for treating cancer by using th-302 alone or in combination with parp inhibitor
WO2023226959A1 (zh) 2022-05-23 2023-11-30 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
EP4591866A1 (en) 2022-09-22 2025-07-30 Ascentawits Pharmaceuticals, Ltd. Use of hypoxia-activated compound in preparation of medicament for treating cancer patient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087684A1 (en) * 2006-02-03 2007-08-09 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340062A (en) 1992-08-13 1994-08-23 Harmon Industries, Inc. Train control system integrating dynamic and fixed data
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US6162930A (en) 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
AU2003216322A1 (en) 2002-02-15 2003-09-09 Rigel Pharmaceuticals, Inc. Inhibitors of tubulin polymerization
US7456214B2 (en) 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
EP1848704A4 (en) 2005-02-14 2011-05-11 Bionomics Ltd Novel tubulin polymerisation inhibitors
US7429681B2 (en) 2005-06-14 2008-09-30 Baylor University Combretastatin analogs with tubulin binding activity
WO2008070908A1 (en) 2006-12-11 2008-06-19 Bionomics Limited Chemical compounds and processes
US8591921B2 (en) * 2008-04-10 2013-11-26 Virginia Commonwealth University Induction of tumor hypoxia for cancer therapy
WO2011063469A1 (en) * 2009-11-27 2011-06-03 Bionomics Limited Tubulin biomarker assay
CA2686587C (en) * 2009-11-27 2018-01-16 Bionomics Limited Combination therapy for treating proliferative diseases
US20110130367A1 (en) * 2009-11-27 2011-06-02 Bionomics Limited Combination Therapy for Treating Proliferative Diseases
ES2877629T3 (es) * 2010-07-12 2021-11-17 Immunogenesis Inc Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087684A1 (en) * 2006-02-03 2007-08-09 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
靶向小分子创新药物;唐军等;《现代生物医学进展》;20101031;第10卷(第20期);第3997-4000,3972页 *

Also Published As

Publication number Publication date
JP6005855B2 (ja) 2016-10-12
CN104703595A (zh) 2015-06-10
AU2013204313A1 (en) 2013-12-19
NZ630465A (en) 2015-09-25
EP2854796A4 (en) 2015-10-14
IL235927A0 (en) 2015-01-29
WO2013177633A1 (en) 2013-12-05
AU2013204313C1 (en) 2016-04-07
CA2874778A1 (en) 2013-12-05
IL235927A (en) 2017-11-30
AU2013204313B2 (en) 2015-09-03
AU2013270425A1 (en) 2014-12-18
HK1207286A1 (en) 2016-01-29
US20150133401A1 (en) 2015-05-14
JP2015518008A (ja) 2015-06-25
EP2854796A1 (en) 2015-04-08
EP2854796B1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
CN104703595B (zh) 涉及血管破坏剂和靶向缺氧的药剂的组合疗法
ES2545340T3 (es) Terapia de la combinación para el tratamiento de enfermedades proliferativas
ES2386299T3 (es) Benzofuranos, benzotiofenos, benzoselenofenos e indoles sustituidos y su uso como inhibidores de la polimerización de tubulina
JP2014511384A (ja) 疾患治療のための４，９−ジヒドロキシ−ナフト［２，３−ｂ］フランの新規エステル
CN116322674B (zh) 用于根除癌症干细胞并诱导damp介导的抗肿瘤免疫反应的一组新型copi/arf1-脂解途径抑制剂和化合物
EP2814480A1 (en) METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS
AU2015264805B2 (en) Combination Therapy
DK2699580T3 (en) DIAZONAMI DISEASES
BR112020009596A2 (pt) combinações de moduladores duplos de irs/stat3 e anticorpos anti pd-1/pd-l1 para tratar câncer
BR112020015745A2 (pt) Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina
CN120282955A (zh) 苯并吡喃酮类化合物、其制备方法及其应用
HK1172257B (en) Combination therapy for treating proliferative diseases
HK1207286B (en) Combinations of a vascular disrupting agent and a hypoxia-targeting agent for use in the treatment of cancer
US20170119727A1 (en) A therapeutic protocol for treating ovarian cancer
US20240124503A1 (en) Heteroaromatic phosphonium salts and their use treating cancer
CN115381815A (zh) 独脚金内酯衍生物在制备线粒体自噬抑制剂中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170728

Termination date: 20210603

CF01 Termination of patent right due to non-payment of annual fee